TAGRISSO is a targeted lung cancer drug under AstraZeneca. It is also the first targeted therapy approved in China for adjuvant treatment of early-stage lung cancer.
Brand Origin:
UK
industry:
Health, Pharma
Service Regions:
China
services:
Marketing, Public Realations
Strategy & Engagement
TAGRISSO
a groundbreaking targeted therapy for lung cancer by AstraZeneca, was introduced to the Chinese market with a comprehensive PR strategy tailored to enhance its visibility and trust within the healthcare community. We worked closely with medical professionals, influencers, and the media to build strategic media relations, generating widespread coverage in health and pharmaceutical outlets.
To further engage stakeholders, we organized high-profile product launch events, creating a platform for experts to discuss its clinical benefits. Additionally, we supported Tagrisso’s positioning through targeted social media campaigns, public welfare initiatives, and collaborations with healthcare organizations to promote awareness and drive adoption.
Impact & Growth
The media relations efforts resulted in consistent, positive coverage of Tagrisso in leading healthcare publications, significantly elevating its profile within the oncology community.
Boosted Tagrisso’s market presence and established it as a trusted treatment option, driving increased awareness and adoption in China.
TAGRISSO
The product launch events generated substantial media buzz, drawing attention to Tagrisso’s innovative role in early-stage lung cancer treatment. Our strategic involvement in public welfare initiatives reinforced the brand’s commitment to improving patient lives, fostering a sense of trust among Chinese healthcare professionals and consumers.
These integrated efforts directly contributed to increased awareness and the growing adoption of Tagrisso as a leading therapy option in China’s oncology market.
